- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2011 (2011), Article ID 896360, 9 pages
APOE and FABP2 Polymorphisms and History of Myocardial Infarction, Stroke, Diabetes, and Gallbladder Disease
1Karmanos Cancer Institute, School of Medicine, Wayne State University, 4100 John R. Street, Detroit, MI 48201, USA
2Department of Pathology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
3Department of Obstetrics and Gynecology, School of Medicine, Wayne State University, Detroit, MI 48201, USA
4Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
5Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, MI 48201, USA
Received 24 February 2011; Revised 11 May 2011; Accepted 20 June 2011
Academic Editor: Bruce Griffin
Copyright © 2011 Ikuko Kato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. B. Jump, D. Botolin, Y. Wang, J. Xu, and B. Christian, “Fatty acids and gene transcription,” Scandinavian Journal of Food and Nutrition, vol. 50, no. 2, pp. 5–12, 2006.
- C. J. Willer, S. Sanna, A. U. Jackson et al., “Newly identified loci that influence lipid concentrations and risk of coronary artery disease,” Nature Genetics, vol. 40, no. 2, pp. 161–169, 2008.
- M. Beekman, B. T. Heijmans, N. G. Martin et al., “Heritabilities of apolipoprotein and lipid levels in three countries,” Twin Research, vol. 5, no. 2, pp. 87–97, 2002.
- D. I. Boomsma, H. J. M. Kempen, J. A. Gevers Leuven, L. Havekes, P. De Knijff, and R. R. Frants, “Genetic analysis of sex and generation differences in plasma lipid, lipoprotein, and apolipoprotein levels in adolescent twins and their parents,” Genetic Epidemiology, vol. 13, no. 1, pp. 49–60, 1996.
- D. A. Heller, U. de Faire, N. L. Pedersen, G. Dahlén, and G. E. McClearn, “Genetic and environmental influences on serum lipid levels in twins,” The New England Journal of Medicine, vol. 328, no. 16, pp. 1150–1156, 1993.
- A. Iliadou, P. Lichtenstein, U. de Faire, and N. L. Pedersen, “Variation in genetic and environmental influences in serum lipid and apolipoprotein levels across the lifespan in Swedish male and female twins,” American Journal of Medical Genetics, vol. 102, no. 1, pp. 48–58, 2001.
- G. V. Z. Dedoussis, “Apolipoprotein polymorphisms and familial hypercholesterolemia,” Pharmacogenomics, vol. 8, no. 9, pp. 1179–1189, 2007.
- A. M. Minihane, “Fatty acid-genotype interactions and cardiovascular risk,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 82, no. 4–6, pp. 259–264, 2010.
- P. Perez-Martinez, J. Lopez-Miranda, F. Perez-Jimenez, and J. M. Ordovas, “Influence of genetic factors in the modulation of postprandial lipemia,” Atherosclerosis Supplements, vol. 9, no. 2, pp. 49–55, 2008.
- S. Kathiresan, O. Melander, C. Guiducci et al., “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans,” Nature Genetics, vol. 40, no. 2, pp. 189–197, 2008.
- S. Kathiresan, C. J. Willer, G. M. Peloso et al., “Common variants at 30 loci contribute to polygenic dyslipidemia,” Nature Genetics, vol. 41, no. 1, pp. 56–65, 2009.
- J. E. Eichner, S. T. Dunn, G. Perveen, D. M. Thompson, K. E. Stewart, and B. C. Stroehla, “Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review,” American Journal of Epidemiology, vol. 155, no. 6, pp. 487–495, 2002.
- K. Greenow, N. J. Pearce, and D. P. Ramji, “The key role of apolipoprotein e in atherosclerosis,” Journal of Molecular Medicine, vol. 83, no. 5, pp. 329–342, 2005.
- D. M. Hatters, C. A. Peters-Libeu, and K. H. Weisgraber, “Apolipoprotein E structure: insights into function,” Trends in Biochemical Sciences, vol. 31, no. 8, pp. 445–454, 2006.
- A. M. Minihane, L. Jofre-Monseny, E. Olano-Martin, and G. Rimbach, “ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation,” Proceedings of the Nutrition Society, vol. 66, no. 2, pp. 183–197, 2007.
- A. M. Bennet, E. Di Angelantonio, Z. Ye et al., “Association of apolipoprotein E genotypes with lipid levels and coronary risk,” Journal of the American Medical Association, vol. 298, no. 11, pp. 1300–1311, 2007.
- P. W. Wilson, E. J. Schaefer, M. G. Larson, and J. M. Ordovas, “Apolipoprotein E alleles and risk of coronary disease. A meta-analysis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 10, pp. 1250–1255, 1996.
- Y. Song, M. J. Stampfer, and S. Liu, “Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease,” Annals of Internal Medicine, vol. 141, no. 2, pp. 137–147, 2004.
- G. D. Kolovou, D. Damaskos, K. Anagnostopoulou, and D. V. Cokkinos, “Apolipoprotein E gene polymorphism and gender,” Annals of Clinical and Laboratory Science, vol. 39, no. 2, pp. 120–133, 2009.
- D. Gómez-Coronado, J. J. Alvarez, A. Entrala, J. M. Olmos, E. Herrera, and M. A. Lasunción, “Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins,” Atherosclerosis, vol. 147, no. 1, pp. 167–176, 1999.
- K. E. Zerba, R. E. Ferrell, and C. F. Sing, “Genotype-environment interaction: apolipoprotein E (ApoE) gene effects and age as an index of time and spatial context in the human,” Genetics, vol. 143, no. 1, pp. 463–478, 1996.
- R. Elosua, J. M. Ordovas, L. A. Cupples et al., “Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study,” Journal of Lipid Research, vol. 45, no. 10, pp. 1868–1875, 2004.
- R. Frikke-Schmidt, B. G. Nordestgaard, B. Agerholm-Larsen, P. Schnohr, and A. Tybjaerg-Hansen, “Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype,” Journal of Lipid Research, vol. 41, no. 11, pp. 1812–1822, 2000.
- C. Lahoz, E. J. Schaefer, L. A. Cupples et al., “Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study,” Atherosclerosis, vol. 154, no. 3, pp. 529–537, 2001.
- R. W. Mahley, J. Pépin, K. E. Palaoǧlu, M. J. Malloy, J. P. Kane, and T. P. Bersot, “Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype,” Journal of Lipid Research, vol. 41, no. 8, pp. 1290–1301, 2000.
- L. J. Baier, J. C. Sacchettini, W. C. Knowler et al., “An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance,” Journal of Clinical Investigation, vol. 95, no. 3, pp. 1281–1287, 1995.
- L. J. Baier, C. Bogardus, and J. C. Sacchettini, “A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells,” Journal of Biological Chemistry, vol. 271, no. 18, pp. 10892–10896, 1996.
- A. Georgopoulos, O. Aras, and M. Y. Tsai, “Codon-54 polymorphism of the fatty acid-binding protein 2 gene is associated with elevation of fasting and postprandial triglyceride in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 9, pp. 3155–3160, 2000.
- R. A. Hegele, P. W. Connelly, A. J. G. Hanley, F. Sun, S. B. Harris, and B. Zinman, “Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 6, pp. 1060–1066, 1997.
- J. Pihlajamäki, J. Rissanen, S. Heikkinen, L. Karjalainen, and M. Laakso, “A codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 6, pp. 1039–1044, 1997.
- H. M. Vidgren, R. H. Sipiläinen, S. Heikkinen, M. Laakso, and M. I. J. Uusitupa, “Threonine allele in codon 54 of the fatty acid binding protein 2 gene does not modify the fatty acid composition of serum lipids in obese subjects,” European Journal of Clinical Investigation, vol. 27, no. 5, pp. 405–408, 1997.
- J. J. Ågren, R. Valve, H. Vidgren, M. Laakso, and M. Uusitupa, “Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 10, pp. 1606–1610, 1998.
- J. J. Ågren, H. M. Vidgren, R. S. Valve, M. Laakso, and M. I. Uusitupa, “Postprandial responses of individual fatty acids in subjects homozygous for the threonine- or alanine-encoding allele in codon 54 of the intestinal fatty acid binding protein 2 gene,” American Journal of Clinical Nutrition, vol. 73, no. 1, pp. 31–35, 2001.
- K. Yamada, X. Yuan, S. Ishiyama et al., “Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men,” Diabetologia, vol. 40, no. 6, pp. 706–710, 1997.
- R. A. Hegele, T. K. Young, and P. W. Connelly, “Are Canadian Inuit at increased genetic risk for coronary heart disease?” Journal of Molecular Medicine, vol. 75, no. 5, pp. 364–370, 1997.
- A. Georgopoulos, H. Bloomfield, D. Collins et al., “Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT),” Atherosclerosis, vol. 194, no. 1, pp. 169–174, 2007.
- K. Nishihama, Y. Yamada, H. Matsuo et al., “Association of gene polymorphisms with myocardial infarction in individuals with or without conventional coronary risk factors,” International Journal of Molecular Medicine, vol. 19, no. 1, pp. 129–141, 2007.
- M. Oguri, K. Kato, K. Yokoi et al., “Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome,” Atherosclerosis, vol. 206, no. 2, pp. 486–493, 2009.
- P. Wanby, P. Palmquist, I. Rydén, L. Brattström, and M. Carlsson, “The FABP2 gene polymorphism in cerebrovascular disease,” Acta Neurologica Scandinavica, vol. 110, no. 6, pp. 355–360, 2004.
- Y. Yamada, K. Kato, M. Oguri et al., “Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome,” International Journal of Molecular Medicine, vol. 21, no. 6, pp. 801–808, 2008.
- C. Albala, A. Villarroel, J. L. Santos et al., “FABP2 Ala54Thr polymorphism and diabetes in Chilean elders,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 245–250, 2007.
- I. Kato, S. Land, A. P. Majumdar, J. Barnholtz-Sloan, and R. K. Severson, “Functional polymorphisms to modulate luminal lipid exposure and risk of colorectal cancer,” Cancer Epidemiology, vol. 34, no. 3, pp. 291–297, 2010.
- G. Block, M. Woods, A. Potosky, and C. Clifford, “Validation of a self-administered diet history questionnaire using multiple diet records,” Journal of Clinical Epidemiology, vol. 43, no. 12, pp. 1327–1335, 1990.
- G. Block, F. E. Thompson, A. M. Hartman, F. A. Larkin, and K. E. Guire, “Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period,” Journal of the American Dietetic Association, vol. 92, no. 6, pp. 686–693, 1992.
- A. K. Wirfält, R. W. Jeffery, and P. J. Elmer, “Comparison of food frequency questionnaires: the reduced Block and Willett questionnaires differ in ranking on nutrient intakes,” American Journal of Epidemiology, vol. 148, no. 12, pp. 1148–1156, 1998.
- W. Willett and M. J. Stampfer, “Total energy intake: implications for epidemiologic analyses,” American Journal of Epidemiology, vol. 124, no. 1, pp. 17–27, 1986.
- N. E. Breslow and N. E. Day, “Statistical methods in cancer research, vol 1, the analysis of case-control studies,” International Aerial Robotics Competition Scientific Publications, no. 32, pp. 5–338, 1980.
- S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.
- C. A. Wiwi and D. J. Waxman, “Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450,” Growth Factors, vol. 22, no. 2, pp. 79–88, 2004.
- D. J. Waxman and C. O'Connor, “Growth hormone regulation of sex-dependent liver gene expression,” Molecular Endocrinology, vol. 20, no. 11, pp. 2613–2629, 2006.
- J. Oscarsson, S. O. Olofsson, K. Vikman, and S. Edén, “Growth hormone regulation of serum lipoproteins in the rat: different growth hormone regulatory principles for apolipoprotein (apo) B and the sexually dimorphic apo E concentrations,” Metabolism, vol. 40, no. 11, pp. 1191–1198, 1991.
- N. Ståhlberg, E. Rico-Bautista, R. M. Fisher et al., “Female-predominant expression of fatty acid translocase/CD36 in rat and human liver,” Endocrinology, vol. 145, no. 4, pp. 1972–1979, 2004.
- J. Oscarsson and S. Edén, “Sex differences in fatty acid composition of rat liver phosphatidylcholine are regulated by the plasma pattern of growth hormone,” Biochimica et Biophysica Acta, vol. 959, no. 3, pp. 280–287, 1988.
- G. G. Martin, B. P. Atshaves, A. L. McIntosh, J. T. Mackie, A. B. Kier, and F. Schroeder, “Liver fatty acid binding protein gene ablation potentiates hepatic cholesterol accumulation in cholesterol-fed female mice,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 290, no. 1, pp. G36–G48, 2006.
- Y. Xie, E. P. Newberry, S. M. Kennedy, J. Luo, and N. O. Davidson, “Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein knockout mice,” Journal of Lipid Research, vol. 50, no. 5, pp. 977–987, 2009.
- Y. Kawashima, J. Chen, H. Sun et al., “Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus,” Diabetologia, vol. 52, no. 7, pp. 1434–1441, 2009.
- L. A. Profenno and S. V. Faraone, “Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population,” American Journal of Medical Genetics—Part B, vol. 147B, no. 6, pp. 822–829, 2008.
- F. I. Errera, M. E. Silva, E. Yeh et al., “Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 7, pp. 883–888, 2006.
- A. Tavridou, K. I. Arvanitidis, A. Tiptiri-Kourpeti et al., “Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population,” Diabetes Research and Clinical Practice, vol. 84, no. 2, pp. 132–137, 2009.
- D. E. Johnston and M. M. Kaplan, “Pathogenesis and treatment of gallstones,” The New England Journal of Medicine, vol. 328, no. 6, pp. 412–421, 1993.
- Y. A. Kesäniemi, C. Ehnholm, and T. A. Miettinen, “Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype,” Journal of Clinical Investigation, vol. 80, no. 2, pp. 578–581, 1987.
- T. A. Miettinen, H. Gylling, H. Vanhanen, and A. Ollus, “Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes,” Arteriosclerosis and Thrombosis, vol. 12, no. 9, pp. 1044–1052, 1992.
- H. Gylling, K. Aalto-Setälä, K. Kontula, and T. A. Miettinen, “Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia,” Arteriosclerosis and Thrombosis, vol. 11, no. 5, pp. 1368–1375, 1991.
- H. Gylling, K. Kontula, and T. A. Miettinen, “Cholesterol absorption and metabolism and LDL kinetics in healthy men with different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 2, pp. 208–213, 1995.
- H. Gylling, K. Kontula, U. M. Koivisto, H. E. Miettinen, and T. A. Miettinen, “Polymorpohisms of the genes encoding apoproteins A-I, B, C-III, and E and LDL receptor, and cholesterol and LDL metabolism during increased cholesterol intake,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 1, pp. 38–44, 1997.
- M. Niemi, K. Kervinen, A. Rantala et al., “The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects,” Gut, vol. 44, no. 4, pp. 557–562, 1999.
- A. Bertomeu, E. Ros, D. Zambón et al., “Apolipoprotein E polymorphism and gallstones,” Gastroenterology, vol. 111, no. 6, pp. 1603–1610, 1996.
- S. Fischer, M. H. Dolu, B. Zündt, G. Meyer, S. Geisler, and D. Jüngst, “Apolipoprotein E polymorphism and lithogenic factors in gallbladder bile,” European Journal of Clinical Investigation, vol. 31, no. 9, pp. 789–795, 2001.
- K. J. van Erpecum, P. Portincasa, M. H. Dohlu, G. P. van Berge-Henegouwen, and D. Jüngst, “Biliary pronucleating proteins and apolipoprotein E in cholesterol and pigmentstone patients,” Journal of Hepatology, vol. 39, no. 1, pp. 7–11, 2003.
- P. Portincasa, K. J. van Erpecum, P. C. van De Meeberg, G. M. Dallinga-Thie, T. W. A. De Bruin, and G. P. Van Berge-Henegouwen, “Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy,” Hepatology, vol. 24, no. 3, pp. 580–587, 1996.
- M. Dixit, G. Choudhuri, and B. Mittal, “Association of APOE-C1 gene cluster polymorphisms with gallstone disease,” Digestive and Liver Disease, vol. 38, no. 6, pp. 397–403, 2006.
- Z. Y. Jiang, T. Q. Han, G. J. Suo et al., “Polymorphisms at cholesterol 7α-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease,” World Journal of Gastroenterology, vol. 10, no. 10, pp. 1508–1512, 2004.
- K. Hasegawa, S. Terada, K. Kubota et al., “Effect of apolipoprotein E polymorphism on bile lipid composition and the formation of cholesterol gallstone,” American Journal of Gastroenterology, vol. 98, no. 7, pp. 1605–1609, 2003.
- C. W. Ko. Cynthia, S. A. A. Beresford, B. Alderman et al., “Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy,” Hepatology, vol. 31, no. 1, pp. 18–23, 2000.
- Q. Y. Lin, J. P. Du, M. Y. Zhang et al., “Effect of apolipoprotein E gene Hha I restricting fragment length polymorphism on serum lipids in cholecystolithiasis,” World Journal of Gastroenterology, vol. 5, no. 3, pp. 228–230, 1999.
- L. L. Boland, A. R. Folsom, E. Boerwinkle, et al., “Atherosclerosis Risk in Communities (ARIC) Study Investigators. Apolipoprotein E genotype and gallbladder disease risk in a large population-based cohort,” Annals of Epidemiology, vol. 16, no. 10, pp. 763–769, 2006.
- H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans, “Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice,” Journal of Lipid Research, vol. 50, no. 6, pp. 1090–1100, 2009.
- C. Bosetti, A. Tavani, E. Negri, D. Trichopoulos, and C. La Vecchia, “Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls,” Journal of Clinical Epidemiology, vol. 54, no. 9, pp. 902–906, 2001.
- O. H. Klungel, A. de Boer, A. H. P. Paes, J. C. Seidell, and A. Bakker, “Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records,” Netherlands Journal of Medicine, vol. 55, no. 4, pp. 177–183, 1999.
- F. Kee, L. Tiret, J. Y. Robo et al., “Reliability of reported family history of myocardial infarction,” British Medical Journal, vol. 307, no. 6918, pp. 1528–1530, 1993.